CCL2 and cardiovascular disorder: Despite the changes implying that RCA may favor infection, the decreased levels of inflammatory markers (particularly MCP-1) and risk factors (e.g., plasma phosphate and FGF 23) could also indicate that patients receiving RCA are at lower risk of cardiovascular disease than patients receiving SHA [31,33,34,35,36].